Is CHD a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Church & Dwight (CHD) rests on Power-brand and personal-care mix: A concentrated set of power brands (Arm & Hammer, OxiClean, Trojan, Batiste, TheraBreath, Waterpik, Hero Cosmetics) generates most of the revenue, and the faster-growing personal-care names give CHD a higher-growth tilt than a pure household-products company. The bear case rests on u.S. Analysts covering it publish targets from $78.00 to $115.00 against a $104.53 price, so even the professionals disagree by 35% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Church & Dwight is an American consumer packaged goods company headquartered in Ewing, New Jersey, that makes household, personal-care and specialty products. It sells more than 80 brands, but roughly a dozen "power brands" (Arm & Hammer, OxiClean, Trojan, Nair, First Response, Orajel, Batiste, Waterpik, TheraBreath, Hero Cosmetics and others) drive the bulk of revenue. The mix blends slow-and-steady staples like baking soda and laundry additives with faster-growing personal-care acquisitions, and the company has a long track record of bolt-on M&A and consistent dividend increases. The investment picture is that of a defensive compounder. CHD posts modest but reliable organic growth, expanding gross margins from productivity programs, and strong free cash flow, which supports buybacks and a multi-decade dividend history. The tension is valuation: the stock trades around 33x trailing earnings (about 26x forward) as of October 2026, a premium to the household-products group, at a time when U.S. organic growth has been soft and the 2026 plan leans on new-product launches and back-half execution. Bulls point to margin gains and the personal-care pivot, while skeptics see a stretched multiple against muted domestic demand and heavy competition from far larger rivals. The latest reported quarter, ended June 30, 2026, brought net sales of about $1.53 billion, up roughly 1.6% year over year, and net income of about $203 million. Earnings per share of $0.89 came in a cent below the $0.90 consensus, the first miss after several quarters of small beats. The market has looked past it: CHD closed at $103.36 on October 16, 2026, up about 25% year to date and about 18% over one year, as investors rotated toward defensive staples. Analyst views are split on how much further it can run, with UBS at $106 (Neutral) and Barclays at $83. Third-quarter results are due October 30, 2026, with consensus EPS of $0.90 on about $1.58 billion of sales.
The bull case: what would have to be true for $115.00
The most optimistic published target on CHD is $115.00, +10.0% from the $104.53 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Power-brand and personal-care mix
A concentrated set of power brands (Arm & Hammer, OxiClean, Trojan, Batiste, TheraBreath, Waterpik, Hero Cosmetics) generates most of the revenue, and the faster-growing personal-care names give CHD a higher-growth tilt than a pure household-products company. Continued innovation, notably around TheraBreath toothpaste, is central to the 2026 growth story.
2. Margin expansion and productivity
Adjusted gross margin expanded about 130 basis points to roughly 46.4% in Q1 2026 as productivity programs, acquisitions and favorable FX more than offset inflation and tariff costs. Sustained gross-margin gains are a key lever for the 5% to 8% adjusted EPS growth the company targets for 2026. Over the trailing twelve months gross margin is about 45.6% and operating margin about 18%.
3. Cash generation and shareholder returns
CHD guided to roughly $1.15 billion of free cash flow in 2026, funding a long-running dividend (a dividend aristocrat with decades of increases) plus buybacks and bolt-on acquisitions. Trailing operating cash flow is about $1.26 billion. The dividend is about $1.23 per share a year, a yield near 1.2% at the October 16, 2026 price, with a payout ratio around 39% of earnings.
4. Bolt-on M&A engine
Acquisitions like Waterpik, TheraBreath, Hero Cosmetics and Touchland have historically refreshed the portfolio toward higher-growth categories. Continued disciplined dealmaking is part of how management aims to offset slower legacy-brand growth.
The bear case: what would have to be true for $78.00
The most pessimistic published target is $78.00, -25.4% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Church & Dwight is worth if the risks below bite instead of the drivers above.
U.S. organic growth has been soft, with some domestic categories declining, so 2026 guidance is back-half weighted and carries execution risk on new-product launches. At around 33x trailing earnings after a 25% run in 2026, the valuation is a premium to the household-products group and leaves little margin for error if volumes or margins disappoint. The company competes with far larger rivals such as Procter & Gamble and Colgate-Palmolive that have bigger marketing budgets and shelf presence. Input-cost inflation, tariffs and private-label competition can pressure margins, and CHD faces routine product-related consumer litigation typical of large CPG companies. A separate SEC proxy-disclosure matter involving a former CEO was settled in 2024 and is not an active securities-fraud case. The second quarter of 2026 showed only about 1.6% sales growth and a one-cent EPS miss, so the back-half acceleration the guidance needs has yet to show up in reported numbers.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CHD already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CHD
19 analysts cover CHD, with an average target of $104.63 (+0.1% against $104.53) and a split of 10 buy, 9 hold, 2 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CHD forecast and price target page.
How is CHD valued? (as of October 2026)
Snapshot for CHD as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$6.2 billion; Q2 2026 ~$1.53 billion, +1.6% YoY
- Margins: Gross ~45.6%; operating ~18%; net ~12%
- Net income (TTM): ~$745 million; trailing EPS ~$3.12
- Q2 2026 EPS: $0.89 vs $0.90 expected
- P/E: ~33x trailing; ~26x forward
- Dividend yield: ~1.2% ($1.23 a year)
- Market cap: ~$24.5 billion at $103.36 (Oct 16, 2026)
- 2026 FCF guide: ~$1.15 billion (trailing FCF ~$940 million)
CHD's multiple has expanded in 2026 as the stock rose about 25% while sales grew in the low single digits, so the shares now sit close to the analysts' average target of about $105. The premium reflects its defensive profile and margin expansion, but it assumes the back-half-weighted 2026 plan delivers, which the October 30, 2026 report (consensus EPS $0.90) will start to show.
How do you decide if CHD is a buy?
Rather than asking whether CHD is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CHD indirectly through an index or sector ETF before adding more.
What would change your mind on CHD
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Power-brand and personal-care mix stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: u.S fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CHD stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CHD against your real portfolio and see your actual exposure before deciding.
Investing in Church & Dwight with AI
Connect the broker you already use and ask Walnut's AI how CHD fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is CHD a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Power-brand and personal-care mix, with revenue (ttm) at ~$6.2 billion; Q2 2026 ~$1.53 billion, +1.6% YoY. The bear case rests on u.S. Analysts covering it are spread from $78.00 to $115.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CHD?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. U.S. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $78.00, -25.4% from the $104.53 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for CHD?
+
Power-brand and personal-care mix. A concentrated set of power brands (Arm & Hammer, OxiClean, Trojan, Batiste, TheraBreath, Waterpik, Hero Cosmetics) generates most of the revenue, and the faster-growing personal-care names give CHD a higher-growth tilt than a pure household-products company. The most optimistic analyst target on CHD is $115.00, +10.0% from the $104.53 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for CHD?
+
U.S. organic growth has been soft, with some domestic categories declining, so 2026 guidance is back-half weighted and carries execution risk on new-product launches. At around 33x trailing earnings after a 25% run in 2026, the valuation is a premium to the household-products group and leaves little margin for error if volumes or margins disappoint. The company competes with far larger rivals such as Procter & Gamble and Colgate-Palmolive that have bigger marketing budgets and shelf presence. Input-cost inflation, tariffs and private-label competition can pressure margins, and CHD faces routine product-related consumer litigation typical of large CPG companies. A separate SEC proxy-disclosure matter involving a former CEO was settled in 2024 and is not an active securities-fraud case. The second quarter of 2026 showed only about 1.6% sales growth and a one-cent EPS miss, so the back-half acceleration the guidance needs has yet to show up in reported numbers. The most pessimistic published target is $78.00, -25.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Church & Dwight do?
+
Church & Dwight is an American consumer packaged goods company headquartered in Ewing, New Jersey, that makes household, personal-care and specialty products.
What would have to change for CHD to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Power-brand and personal-care mix) stalling in the reported numbers rather than in the narrative, the risk above (u.S) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Church & Dwight do?
+
It is a consumer packaged goods company that makes household, personal-care and specialty products. Its best-known brands include Arm & Hammer, OxiClean, Trojan, Nair, First Response, Orajel, Batiste, Waterpik and TheraBreath.
Is CHD a dividend stock?
+
Yes. Church & Dwight has a decades-long record of paying and raising its dividend, making it a dividend aristocrat. The forward dividend is around $1.23 per share, a yield near 1.2% at the October 16, 2026 price, paid quarterly.
Why does CHD trade at a high P/E?
+
The stock carries a premium multiple (around 33x trailing and 26x forward earnings as of October 2026) because investors value its defensive staples profile, consistent free cash flow, margin expansion and long dividend history. That premium also assumes steady execution.
Walnut is informational, not investment advice, and gives no verdict on CHD. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.